Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Proof-of-concept Trial of Methylphenidate in Children With Apraxia of Speech: a Double-blind, Randomised, Placebo-controlled, Cross-over Trial

NCT05185583 is registered in ClinicalTrials.gov with Murdoch Childrens Research Institute as lead sponsor.

NCT NCT05185583
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05185583 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Proof-of-concept Trial of Methylphenidate in Children With Apraxia of Speech: a Double-blind, Randomised, Placebo-controlled, Cross-over Trial
Lead sponsor
Murdoch Childrens Research Institute
Phase
Phase 2
Overall status
Completed
Start date
March 14, 2022
Completion date
October 27, 2025
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

childhood apraxia of speech